Lexicon Pharmaceuticals (LXRX) Total Non-Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Total Non-Current Liabilities for 17 consecutive years, with $59.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 64.81% year-over-year to $59.6 million; the TTM figure through Mar 2026 stood at $59.6 million (down 64.81% YoY), while the FY2025 annual figure was $70.3 million, down 51.72% from the prior year.
• Total Non-Current Liabilities declined to $59.6 million in Q1 2026 per LXRX's latest filing, from $70.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $169.3 million in Q1 2025 and bottomed at $40.5 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $93.3 million across 5 years, with a median of $78.2 million in 2025.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 224.31% — and 2026, when it plunged 64.81%.
• Lexicon Pharmaceuticals' Total Non-Current Liabilities stood at $71.8 million in 2022, then surged by 82.65% to $131.1 million in 2023, then climbed by 11.06% to $145.5 million in 2024, then sank by 51.72% to $70.3 million in 2025, then fell by 15.22% to $59.6 million in 2026.
• Business Quant data shows LXRX's Total Non-Current Liabilities at $59.6 million in Q1 2026, $70.3 million in Q4 2025, and $78.2 million in Q3 2025.